Larimar Therapeutics (LRMR) Change in Accured Expenses (2013 - 2025)

Larimar Therapeutics' Change in Accured Expenses history runs 13 years deep, the most recent figure standing at $25.8 million for Q4 2025.

• Quarterly Change in Accured Expenses rose 252.91% year-over-year to $25.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $37.6 million (up 179.49% YoY) and the FY2025 annual result came in at $37.6 million, up 179.49% from the prior year.
• Change in Accured Expenses was $25.8 million for Q4 2025 at Larimar Therapeutics, up from $11.3 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $25.8 million in Q4 2025 and bottomed at -$3.6 million in Q3 2024.
• A 5-year average of $2.6 million and a median of $924500.0 in 2022 frame the typical range for Change in Accured Expenses.
• Peak annual rise in Change in Accured Expenses reached 747.18% in 2021, while the deepest fall reached 635.65% in 2021.
• Larimar Therapeutics' Change in Accured Expenses stood at -$1.4 million in 2021, then soared by 152.33% to $719000.0 in 2022, then jumped by 218.78% to $2.3 million in 2023, then jumped by 218.46% to $7.3 million in 2024, then soared by 252.91% to $25.8 million in 2025.
• Business Quant data shows LRMR's Change in Accured Expenses at $25.8 million in Q4 2025, $11.3 million in Q3 2025, and $2.6 million in Q2 2025.